About this trial

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.

Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Eligibility criteria

Qualifiers

Age 18 years or older.

Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).

Eligible for curative intent therapy, with surgical resection of cancer planned.

Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • blood and tissue samples
  • blood and tissue samples

Treatment groups

1,350 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

2
Medical Oncology Associates of San Diego92123, San DiegoCalifornia, United States
Taylor Cancer Research Center43437, MaumeeOhio, United States

Sponsors and collaborators

Paradigm Health

Lead sponsor